Dr. Nanus on Ongoing Studies in the Neoadjuvant Setting for RCC

David M. Nanus, MD
Published: Tuesday, May 02, 2017



David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses ongoing studies in the neoadjuvant setting for patients with renal cell carcinoma (RCC).

In the neoadjuvant setting, there has been many studies predominantly looking at anti-VEGF therapies, explains Nanus. These studies are being done to determine if tumor shrinkage and resectability are improved, will outcomes also improve, or are there postoperative complications?

If you look at these studies, the progression-free survival is the same, states Nanus. The clear role is attempting to prevent the need for dialysis by leaving some kidney behind and shrinking the cancer preoperatively.
 


David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses ongoing studies in the neoadjuvant setting for patients with renal cell carcinoma (RCC).

In the neoadjuvant setting, there has been many studies predominantly looking at anti-VEGF therapies, explains Nanus. These studies are being done to determine if tumor shrinkage and resectability are improved, will outcomes also improve, or are there postoperative complications?

If you look at these studies, the progression-free survival is the same, states Nanus. The clear role is attempting to prevent the need for dialysis by leaving some kidney behind and shrinking the cancer preoperatively.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x